Literature DB >> 9815976

Wnt5a cloning, expression, and up-regulation in human primary breast cancers.

S Lejeune1, E L Huguet, A Hamby, R Poulsom, A L Harris.   

Abstract

Wnt genes are involved in mouse mammary cancer, but their role in human cancer is unknown. Human Wnt5a was cloned from a placental cDNA library and used to assess expression by ribonuclease protection and in situ hybridization in human breast cell lines and in normal, benign, and malignant breast tissues. Human Wnt5a shows over 99% homology at amino acid level with mouse Wnt5a, and 90% with Xenopus Wnt5a. It was expressed only at low levels in breast cell lines and normal breast tissue. Benign proliferations and invasive cancer respectively showed 10-fold and 4-fold higher Wnt5a than normal breast tissues. The greater up-regulation in benign conditions suggests a role in aberrant differentiation. In situ hybridization localized the signal to the epithelial component. Wnt5a is the first member of the Wnt family to demonstrate overexpression in human breast cancer. It was not associated with factors known to affect breast cancer prognosis such as lymph node status or epidermal growth factor receptor status.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9815976

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Wrch-1, a novel member of the Rho gene family that is regulated by Wnt-1.

Authors:  W Tao; D Pennica; L Xu; R F Kalejta; A J Levine
Journal:  Genes Dev       Date:  2001-07-15       Impact factor: 11.361

Review 2.  Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.

Authors:  Caroline M Alexander; Shruti Goel; Saja A Fakhraldeen; Soyoung Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

3.  Exendin-4 promotes pancreatic β-cell proliferation via inhibiting the expression of Wnt5a.

Authors:  Xinger Wu; Weiwei Liang; Hongyu Guan; Juan Liu; Liehua Liu; Hai Li; Xiaoying He; Jing Zheng; Jie Chen; Xiaopei Cao; Yanbing Li
Journal:  Endocrine       Date:  2016-11-09       Impact factor: 3.633

Review 4.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 5.  Gap Junctions and Wnt Signaling in the Mammary Gland: a Cross-Talk?

Authors:  Sabreen F Fostok; Mirvat El-Sibai; Marwan El-Sabban; Rabih S Talhouk
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

6.  WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer.

Authors:  Hirohide Yoshikawa; Kenichi Matsubara; Xiaoling Zhou; Shu Okamura; Takahiko Kubo; Yaeko Murase; Yuko Shikauchi; Manel Esteller; James G Herman; Xin Wei Wang; Curtis C Harris
Journal:  Mol Biol Cell       Date:  2007-08-29       Impact factor: 4.138

7.  Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells.

Authors:  Nicholas Borcherding; David Kusner; Ryan Kolb; Qing Xie; Wei Li; Fang Yuan; Gabriel Velez; Ryan Askeland; Ronald J Weigel; Weizhou Zhang
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

Review 8.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

Review 9.  The complex pathways of Wnt 5a in cancer progression.

Authors:  Tobias Pukrop; Claudia Binder
Journal:  J Mol Med (Berl)       Date:  2007-10-19       Impact factor: 4.599

10.  Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.

Authors:  Silvie Foldynová-Trantírková; Petra Sekyrová; Katerina Tmejová; Eva Brumovská; Ondrej Bernatík; Wulf Blankenfeldt; Pavel Krejcí; Alois Kozubík; Tomás Dolezal; Lukás Trantírek; Vítezslav Bryja
Journal:  Breast Cancer Res       Date:  2010-05-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.